Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer

Pereira, Irislene Costa; Mascarenhas, Isabele Frazão; Capetini, Vinícius Cooper; Ferreira, Paulo Michel Pinheiro; Rogero, Marcelo Macedo; Torres–Leal, Francisco Leonardo

doi:10.1016/j.critrevonc.2022.103796

Cited by 8 publications

(3 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer (BC) is the primary reason for mortality connected to cancer among women worldwide 9 , 10 . Despite continuous medical advances, clinical outcomes for breast cancer patients still need improvement 10 , 11 .…”

Section: Introductionmentioning

confidence: 99%

Immunogenic cell death-related classification reveals prognosis and effectiveness of immunotherapy in breast cancer

Zhu,

Wu,

Zhao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Lack of specific biomarkers and effective drug targets constrains therapeutic research in breast cancer (BC). In this regard, therapeutic modulation of damage-associated molecular patterns (DAMPs)-induced immunogenic cell death (ICD) may help improve the effect of immunotherapy in individuals with BC. The aim of this investigation was to develop biomarkers for ICD and to construct ICD-related risk estimation models to predict prognosis and immunotherapy outcomes of BC. RNA-seq transcriptome information and medical data from individuals with BC (n = 943) were obtained from TCGA. Expression data from a separate BC cohort (GEO: GSE20685) were used for validation. We identified subtypes of high and low ICD gene expression by consensus clustering and assessed the connection between ICD subtypes and tumor microenvironment (TME). In addition, different algorithms were used to construct ICD-based prognostic models of BC. BC samples were categorized into subtypes of high and low ICD expression depending on the expression of genes correlated with ICD. The subtype of ICD high-expression subtypes are correlated with poor prognosis in breast cancer, while ICD low-expression subtypes may predict better clinical outcomes. We also created and verified a predictive signature model depending on four ICD-related genes (ATG5, CD8A, CD8B, and HSP90AA1), which correlates with TME status and predicts clinical outcomes of BC patients. We highlight the connection of ICD subtypes with the dynamic evolution of TME in BC and present a novel ICD-based prognostic model of BC. In clinical practice, distinction of ICD subtype and assessment of ICD-related biomarkers should help guide treatment planning and improve the effectiveness of tumor immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunogenic cell death-related classification reveals prognosis and effectiveness of immunotherapy in breast cancer

Zhu,

Wu,

Zhao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Additionally, we previously found that the anti-cancer effect of curcumin in prostate hormone-refractory prostate cancer cells is determined by the expression level of maspin [39]. Therefore, curcumin holds the potential to be used as a supplementary anti-cancer agent, depending on the patient's profile [40]. However, the role of TM in curcumin treatment in ER + breast cancer is still unknown.…”

Section: Introductionmentioning

confidence: 99%

“…Breast cancer patients often suffer from chemotherapeutic resistance as the cancer cell evolves to acquire several mechanisms to avoid the adverse effects of chemo-drugs [40]. Acquired resistance to chemotherapeutic drugs occurs when cancer cells are exposed to some anti-cancer agents, which triggers the upregulation of several critical multi-drug resistance (MDR) genes [41].…”

Section: Introductionmentioning

confidence: 99%

The Role of Thrombomodulin in Estrogen-Receptor-Positive Breast Cancer Progression, Metastasis, and Curcumin Sensitivity

et al. 2023

View full text Add to dashboard Cite

Estrogen and estrogen receptors (ER) play a key role in breast cancer progression, which can be treated with endocrine therapy. Nevertheless, resistance to endocrine therapies is developed over time. The tumor expression of thrombomodulin (TM) is correlated with favorable prognosis in several types of cancer. However, this correlation has not yet been confirmed in ER-positive (ER+) breast cancer. This study aims to evaluate the role of TM in ER+ breast cancer. Firstly, we found that lower TM expression correlates to poor overall survival (OS) and relapse-free survival (RFS) rates in ER+ breast cancer patients through Kaplan–Meier survival analysis (p < 0.05). Silencing TM in MCF7 cells (TM-KD) increased cell proliferation, migration, and invasion ability. Additionally, TM-KD MCF7 cells showed higher sensitivity (IC50 15 μM) to the anti-cancer agent curcumin than the scrambled control cells. Conversely, overexpression of TM (TM-over) in T47D cells leads to decreased cell proliferation, migration, and invasion ability. Furthermore, TM-over T47D cells showed more resistance (IC50 > 40 μM) to the curcumin treatment. The PI staining, DAPI, and tunnel assay also confirmed that the curcumin-induced apoptosis in TM-KD MCF7 cells was higher (90.34%) than in the scrambled control cells (48.54%). Finally, the expressions of drug-resistant genes (ABCC1, LRP1, MRP5, and MDR1) were determined by qPCR. We found that the relative mRNA expression levels of ABCC1, LRP1, and MDR1 genes after curcumin treatment were higher in scrambled control cells than in TM-KD cells. In conclusion, our results demonstrated that TM plays a suppressive role in the progression and metastasis of ER+ breast cancer, and it regulates curcumin sensitivity by interfering with ABCC1, LRP1, and MDR1 gene expression.

show abstract

Therapeutic potential of tocotrienols as chemosensitizers in cancer therapy

Sailo,

Chauhan,

Hegde

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Chemoresistance is the adaptation of cancer cells against therapeutic agents. When exhibited by cancer cells, chemoresistance helps them to avoid apoptosis, cause relapse, and metastasize, making it challenging for chemotherapeutic agents to treat cancer. Various strategies like dosage modification of drugs, nanoparticle‐based delivery of chemotherapeutics, antibody‐drug conjugates, and so on are being used to target and reverse chemoresistance, one among such is combination therapy. It uses the combination of two or more therapeutic agents to reverse multidrug resistance and improve the effects of chemotherapy. Phytochemicals are known to exhibit chemosensitizing properties and are found to be effective against various cancers. Tocotrienols (T3) and tocopherols (T) are natural bioactive analogs of vitamin E, which exhibit important medicinal value and potential curative properties apart from serving as an antioxidant and nutrient supplement. Notably, T3 exhibits a variety of pharmacological activities like anticancer, anti‐inflammatory, antiproliferative, and so on. The chemosensitizing property of tocotrienol is exhibited by modulating several signaling pathways and molecular targets involved in cancer cell survival, proliferation, invasion, migration, and metastasis like NF‐κB, STATs, Akt/mTOR, Bax/Bcl‐2, Wnt/β‐catenin, and many more. T3 sensitizes cancer cells to chemotherapeutic drugs including cisplatin, doxorubicin, and paclitaxel increasing drug concentration and cytotoxicity. Discussed herewith are the chemosensitizing properties of tocotrienols on various cancer cell types when combined with various drugs and biological molecules.

show abstract

Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer

Cited by 8 publications

References 223 publications

Immunogenic cell death-related classification reveals prognosis and effectiveness of immunotherapy in breast cancer

Immunogenic cell death-related classification reveals prognosis and effectiveness of immunotherapy in breast cancer

The Role of Thrombomodulin in Estrogen-Receptor-Positive Breast Cancer Progression, Metastasis, and Curcumin Sensitivity

Therapeutic potential of tocotrienols as chemosensitizers in cancer therapy

Contact Info

Product

Resources

About